Celgene Corporation (NASDAQ:CELG) dropped -3.03% or -3.22 points to trade at $102.91 per share. As per the latest trading data available, the net money flow stood at $6.83 million as the shares received $110.23 million in upticks and gave away $103.4 million in downticks. The final up/down ratio was at 1.07. On a weekly basis, the stock has seen a change of -4.35%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 1.91. $25.89 million was the inflow in upticks and $13.55 million was the outflow in downticks. For the block trade, the net money flow was $12.34 million.
Currently the company Insiders own 0.96% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.05% . Institutional Investors own 81.31% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -24.94%. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Celgene Corp /De/, Kaplan Gilla had sold 15,967 shares worth of $1,626,079 in a transaction dated April 4, 2016. In this transaction, 15,967 shares were sold at $101.84 per share.
Celgene Corporation (NASDAQ:CELG) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.3 points or 1.26% at $101.61 with 3,194,453 shares getting traded. Post opening the session at $102.84, the shares hit an intraday low of $101.54 and an intraday high of $104.3681 and the price was in this range throughout the day. The company has a market cap of $78,707 million and the number of outstanding shares have been calculated to be 774,601,500 shares. The 52-week high of Celgene Corporation (NASDAQ:CELG) is $140.72 and the 52-week low is $92.98.
Many analysts have stated their opinion on the company shares. BTIG Research downgrades their rating on the shares of Celgene Corporation (NASDAQ:CELG). The current rating of the shares is Neutral. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 1, 2016.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.